Undisclosed PD-1 x CTLA-4 trispecific TRIDENT
/ MacroGenics
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
May 13, 2021
Molecular Templates, Inc. Reports First Quarter 2021 Financial Results
(GlobeNewswire)
- “MT-6402…MTEM expects to start dosing in a first-in-human Phase 1 study in relapsed/refractory patients with PD-L1-positive solid tumors in 2Q21. MTEM expects to provide an update on the Phase 1 study in 4Q21. MTEM expects to initiate a Phase 1 study for an ETB targeting CTLA-4 in 2022…In 2021, MTEM expects to present preclinical data on new targets and new ETBs at medical and scientific conferences.”
New P1 trial • P1 data • Preclinical • Oncology • Solid Tumor
1 to 1
Of
1
Go to page
1